Non-Alcoholic Steatohepatitis Market By Drug Class (Antidiabetic Drugs, Antioxidants, Anti-inflammatory Drugs, Anti-fibrotic Drugs, Other), By Disease Stage (NASH Stage F0, NASH Stage F1, NASH Stage F2, NASH Stage F3, NASH Stage F4), By Route of Administration (Oral, Injectables, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Dec 2024 | Report ID: MI1568 | 230 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Drug Class

  • Antidiabetic Drugs
  • Antioxidants
  • Anti-inflammatory Drugs
  • Anti-fibrotic Drugs
  • Other

By Disease Stage

  • NASH Stage F0
  • NASH Stage F1
  • NASH Stage F2
  • NASH Stage F3
  • NASH Stage F4

By Route of Administration

  • Oral
  • Injectables
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics

By Region

North America

  • The U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

List of Companies:

  • Intercept Pharmaceuticals
  • Genfit
  • Gilead Sciences
  • Madrigal Pharmaceuticals
  • Bristol-Myers Squibb
  • Pfizer
  • Novo Nordisk
  • AbbVie
  • Eli Lilly and Company
  • Hepion Pharmaceuticals
  • Tiziana Life Sciences
  • Merrimack Pharmaceuticals
  • Siegfried Holding
  • Theravance Biopharma
  • Durect Corporation
  • Astellas Pharma
  • Viatris
  • Belite Bio

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing